The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples